Clear Cell Renal Cell Carcinoma Metastases Visibility: Split-Bolus Single Scan vs. Portal Venous Phase CT
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
To assess the impact of split-bolus (SB) single scan CT on the conspicuity of clear cell renal cell carcinoma (ccRCC) metastases compared to single-bolus injection.
Methods
This retrospective cohort study included consecutive patients with histologically proven metastatic ccRCC who underwent both SB and single-bolus portal venous abdominal CT within 6 months between 2017 and 2022 in a single tertiary center. SB CT utilized BMI-adjusted contrast dose and kVp (80-120) with concurrent arterial and portal venous phases. Single bolus CT utilized BMI-adjusted contrast dose at 120kVp at the portal venous phase. Wilcoxon rank test compared the conspicuity of metastases between the protocols.
Results
Of the 47 patients, 80.9% were male, with a mean age of 67 ± 10.4 years and a BMI of 27.1 ± 5.7. There were 48 paired CTs performed with a median interval of 93 days. Contrast dose was 143 ± 27 cc for SB and 108 ± 26 cc for single-bolus ( p < 0.001). 66 metastases were analyzed, with an average size of 2 cm: 48.5% in the pancreas, 28.8% in skeletal muscle, and 22.7% in the liver. The median contrast-to-noise ratio (CNR) was higher with SB compared to single-bolus for all metastases (3.0 vs. 1.4), pancreatic metastases (2.7 vs. 1.4), muscle metastases (5.2 vs. 2.0), and liver metastases (2.8 vs. 0.9), all p < 0.001.
Conclusions
SB scan provides dramatically higher conspicuity of ccRCC metastases as compared to single-bolus portal venous CT.
